Palbociclib in combination with letrozole in patients with Hormone Receptor-positive/HER2-negative residual disease after standard neoadjuvant chemotherapy
Palbociclib in combination with letrozole in patients with Hormone Receptor-positive/HER2-negative residual disease after standard neoadjuvant chemotherapy